Therapy with biologics has brought a paradigm shift in the management of inflammatory bowel disease (IBD). Infliximab (IFX) has remained one of the key drugs for therapy in IBD. Despite Infliximab’s therapeutic effects, roughly 10-30% of patients do not respond to the initial treatment, and 23-46% of patients lose response over time.
In a recent study, researchers wanted to compare measured IFX concentrations with forecast values predicted by the iDose dashboard system. iDose software is based on a Bayesian algorithm designed specifically for managing IBD patients on IFX therapy. In addition, researchers wanted to report iDose’s efficacy in managing patients not responding to conventional dosing schedules.
The study included 30 individuals, 10 ulcerative colitis (UC), and 20 Crohn’s disease (CD) patients on IFX therapy. Amongst these patients, 28 had active disease while 2 were in clinical remission but were high-risk patients. An IFX dose of 5mg was administered to 25 patients, and 5 patients were on 10mg maintenance dose.
iDose-assisted patient management
In this study, researchers entered patient information, such as disease details along with dose, laboratory findings such as albumin, CRP, earlier drug concentration, and ADA status (if available), into the iDose software.
iDose gives a graphical presentation of IFX level attained by a patient on sample collection date and predicts its dose to be given to attain a predetermined IFX concentration. Eleven of the patients were prospectively managed as per iDose forecast and clinical judgment. The outcome, along with IFX concentration, was compared in patients.
Results
IFX monitoring in 30 patients had shown therapeutic concentration in 12, supratherapeutic (greater levels of IFX) in 2 and subtherapeutic (lower levels of IFX) concentration in 16 patients. With iDose-assisted dosing, clinical improvement was seen in 10/11 patients; there was an increase in dosing interval, and thus cost reduction in 3 patients, clinical remission was attained by decreasing dosing interval in 4 patients.
In conclusion, this study found concordance in measured and iDose-forecasted IFX concentration in 70% of patients. The iDose dashboard-assisted patient management improved clinical response in patients with active disease on conventional dosing and has the potential to prevent loss of response and reduce healthcare costs.
Contact Us
At Baysient, we value the fact that all patients are unique and deserve individual treatments tailored specifically for them, changing as they heal. There is no single dose that is right for all patients. That is why our goal is to provide individualized treatments for patients with improved outcomes at lower costs.
iDose, our cloud-based software, uses Bayesian models, routine lab results, and demographic information to allow physicians to individualize dosing to a specific target trough level. Interested in how iDose can improve your patient outcomes? Schedule a Demo today!
